Compounds, compositions comprising the same and their use as pharmaceuticals
Compounds targeting the GIPR effectively treat metabolic diseases and obesity by modulating GIPR activity, addressing the need for GIPR antagonist molecules in existing treatments.
Patent Information
- Application Number
- PCT/CA2026/050664
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
There is a need for the discovery of Glucose-dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist molecules for the treatment of metabolic diseases and obesity, either as single agents or in combination with other incretin modulators.
Development of compounds of Formula I and their pharmaceutical compositions, which include pharmaceutically acceptable salts, solvates, or prodrugs, targeting the GIPR to modulate its activity.
The compounds effectively treat or prevent conditions such as diabetes, obesity, and related metabolic disorders by modulating GIPR activity, demonstrating potential in improving insulin sensitivity and reducing weight gain.
Smart Images

Figure CA2026050664_12112026_PF_FP_ABST
Abstract
Description
COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND THEIR USE AS PHARMACEUTICALSRELATED APPLICATION
[0001] The present application claims priority under applicable law to United States provisional application No. 63 / 801,355, filed on May 7, 2025, the content of which is incorporated herein by reference in its entirety and for all purposes.TECHNICAL FIELD
[0002] The technical field generally relates to compounds, pharmaceutical compositions containing the compounds and their uses as Glucose-dependent Insulinotropic Polypeptide Receptor (Gl PR) antagonists.BACKGROUND
[0003] Glucose-dependent insulinotropic polypeptide (GIP, formerly called gastric inhibitory polypeptide) is a 42-amino acid peptide secreted from K-cells in the proximal small intestine in response to food ingestion. GIP is a member of the incretin family of peptides and enhances glucose-dependent insulin secretion. GIP is also known to promote fat storage in adipose tissue and also influences bone metabolism (see Baggio & Drucker Gastroenterology 2007, 132,2131; Hansen et al. Br J Pharmacol. 2016,173,826.; Holst et al. J Clin Endocrinol Metab. 2020 ,105, 2710).
[0004] The GIP receptor (G I PR) is a class B1 G protein-coupled receptor (GPCR) of the glucagon subfamily and is characterized by an extracellular domain at the N-terminus, seven transmembrane domains and an intracellular domain at the C-terminus (see Zhao et al. Nat. Commun. 2022, 72, 1057). GIPR is expressed in various tissues, including the gut, adipose tissue, the pancreas, the vasculature and the brain (see Hammoud et al. Nat. Rev. Endocrinol.2023, 18, 201). The extracellular domain serves to recognize its natural peptide agonist GIP, which results in a conformational change from inactive to active, triggering an increase in cAMP production mediated by Gas.
[0005] GIPR knockout mice are resistant to high fat diet-induced weight gain and have been shown to have improved insulin sensitivity and lipid profiles (see Yamada et al. Diabetes 2006, 55, S86 and Miyawaki et al. Nature Med. 2002, 8, 738). This observation has been translated tohumans, where it has been observed that heterozygous loss of function of GIPR results in lower obesity risk and overall BMI (see Akbari et al. Science 2021, 373, 6550). Pre-clinical pharmacological translation of these effects have been observed using small molecules, peptides and antibodies with antagonistic activities (see Nakamura et al. Diabetes Metab. Syndr. Obes.2021, 14, 1095; Yang et al. Mol. Metab. 2022, 66, 101638; Killion et al. Sci. Transl. Med. 2018, 10, eaat3392). Furthermore, synergy has been demonstrated between GIPR modulators and GLP-1 agonists to lead to superior weight loss (see Lu etal. Cell Rep. Med. 2021, 2, 100263).
[0006] There is thus a need for the discovery of GIPR antagonist molecules and their use in the treatment of metabolic diseases and obesity, either as single agents or in combination with other incretin modulators.SUMMARY
[0007] According to one aspect, the present technology relates to a compound of Formula I:oJL / XlN X HY4=YVBH0(I)or a pharmaceutical acceptable salt, solvate, or prodrug thereof,wherein:X is selected from -CR2R2’-, -O- and -NR2-;XIis selected from -CR1R1’-, -O- and -NR1-;X3is selected from -O-, -NH- and -S-;X4is selected from -N=, -CH= and -CR7=;provided that when one of X and X1is -CR2R2’- or -CR1R1’-, then the other of X and X1is other than -CR2R2’- or -CR1R1’-, and provided that when one of X and X1is - O-, -NR1- or -NR2-, then the other of X and X1is other than -O-, -NR1- or -NR2-;Y1, Y2, Y3and Y4are independently selected from -N=, -CH= and -CR8=, and one _ O CB— \ of Y1, Y2, Y3and Y4is -C= to allow the connection with OH ; R1, R1’, R2and R2’ are independently selected from -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’; or R1and R2are taken together with their adjacent atoms to form a ring, the ring being optionally substituted with one or more substituents; or R1and R1’ are taken together with their adjacent carbon atom to form a ring, the ring being optionally substituted with one or more substituents; or R2and R2’ are taken together with their adjacent carbon atom to form a ring, the ring being optionally substituted with one or more substituents;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;R7is a linear or branched Ci-Cealkyl;R8is selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, -NR4S(=O)2-R5and -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;( A )' is selected from the group consisting of 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl each optionally linked to NH through a Ci-Cealkyl group, the 4- to 14-membered heterocycloalkyl, Ce-Cwaryl or 5- to 10-membered heteroaryl being optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -OR3, SFs, or -SR3, wherein the linear or branched Ci-Cealkyl and Cs-Cscycloalkyl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3; and( B )- is selected from the group consisting of linear or branched Ci-Cealkyl, C2-Csalkyne, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, the linear or branched Ci-Cealkyl, C2-Csalkyne, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl or 5- to 10-membered heteroaryl being optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -C(=O)OH, -OR3, -SFs, or -SR3, wherein the linear orbranched Ci-Cealkyl and Cs-Cscycloalkyl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or - CF3.
[0008] The present technology also relates to any examples and embodiments of these compounds as further described herein.
[0009] In another aspect, the present technology further relates to pharmaceuticals compositions comprising a compound as herein defined together with a pharmaceutically acceptable carrier, diluent or excipient.
[0010] In a further aspect, this technology also relates to uses and methods for the treatment or prevention of a condition, a disease or a disorder for which modulating the glucose-dependent insulinotropic polypeptide receptor (GIPR) is indicated.
[0011] In a further aspect, this technology also relates to uses and methods for the treatment or prevention of a condition, a disease or a disorder selected from metabolic diseases and obesity.
[0012] In a further aspect, this technology also relates to uses and methods for the treatment or prevention of selected from diabetes (e.g. Type 1 diabetes mellitus (T1D), Type 2 diabetes mellitus (T2DM), including pre-diabetes), idiopathic T1D (Type 1b), latent autoimmune diabetes in adults (LADA), early-onsetT2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, or chronic kidney disease (CKD)), diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea (e.g. obstructive sleep apnea (OSA)), obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urine incontinence), eating disorders (including binge eating syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndromes), weight gain such as weight gain caused by use of other agents (e.g., caused by use of steroids and / or antipsychotics, or caused by treatment of depression, or caused by use of agents on cognitive function), excessive sugar craving, dyslipidemia [including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high LDL (low-density lipoprotein) cholesterol, and low HDL (high-density lipoprotein) cholesterol], hyperinsulinemia, nonalcoholic fatty liver disease [NAFLD, including related diseases such as steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma], cardiovascular disease,atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, heart failure (e.g. congestive heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF)), myocardial infarction (e.g. necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, osteoarthritis, Parkinson’s disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, polycystic ovary syndrome (PCOS), and addiction (e.g., addiction to alcohol, nicotine, and / or drug).
[0013] Additional objects and features of the present compounds, compositions, methods and uses will become more apparent upon reading of the following non-restrictive description of exemplary embodiments and examples section, which should not be interpreted as limiting the scope of the invention.DETAILED DESCRIPTION
[0014] All technical and scientific terms and expressions used herein have the same definitions as those commonly understood by a person skilled in the art to which the present technology pertains. The definition of some terms and expressions used is nevertheless provided below. To the extent the definitions of terms in the publications, patents, and patent applications incorporated herein by reference are contrary to the definitions set forth in this specification, the definitions in this specification will control. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter disclosed.General Definitions
[0015] Chemical structures described herein are drawn according to conventional standards. Also, when an atom, such as a carbon atom, as drawn seems to include an incomplete valency, then the valency is assumed to be satisfied by one or more hydrogen atoms even though theseare not necessarily explicitly drawn. Hydrogen atoms should be inferred to be part of the compound.
[0016] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. It should be noted that, the singular forms "a", "an", and "the" include plural forms as well, unless the content clearly dictates otherwise. Thus, for example, reference to a composition containing "a compound" also contemplates a mixture of two or more compounds. It should also be noted that the term "or" is generally employed in its sense including "and / or" unless the context clearly dictates otherwise. Furthermore, to the extent that the terms “including”, "includes", "having", "has", "with", or variants thereof are used in either the detailed description and / or the claims, such terms are intended to be inclusive in a manner similar to the term "comprising”.
[0017] The term "about" or "approximately" means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, "about" can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and more preferably still up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term "about" meaning within an acceptable error range for the particular value should be assumed.
[0018] As used herein, the terms "compounds”, "compounds herein described", "compounds of the present application", “compounds as defined herein” and equivalent expressions refer to compounds described in the present application, e.g. those encompassed by structural Formula I, optionally with reference to any of the applicable embodiments, and also includes exemplary compounds, such as Compounds 1 to 11, as well as their pharmaceutically acceptable salts, solvates, and prodrugs when applicable. When a zwitterionic form is possible, the compound may be drawn as its neutral form for practical purposes, but the compound is understood to also include its zwitterionic form. Embodiments herein may also exclude one or more of the compounds. Compounds may be identified either by their chemical structure or their chemical name. In a case where the chemical structure and chemical name would conflict, the chemical structure will prevail.
[0019] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure when applicable; for example, the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the present description. The therapeutic compound unless otherwise noted, also encompasses all possible tautomeric forms of the illustrated compound, if any. The term also includes isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass most abundantly found in nature. Examples of isotopes that may be incorporated into the present compounds include, but are not limited to,2H (D),3H (T),11C,13C,14C,15N,18O,17O, any one of the isotopes of sulfur, etc. The compound may also exist in unsolvated forms as well as solvated forms, including hydrated forms. The compound may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated herein and are intended to be within the scope of the present invention.
[0020] Where a particular enantiomer is preferred, it may, in some embodiments be provided substantially free of the corresponding enantiomer and may also be enantiomerically enriched. "Enantiomerically enriched" means that the compound is made up of a significantly greater proportion of one enantiomer. In certain embodiments the compound is made up of at least about 90% by weight of a preferred enantiomer. In other embodiments the compound is made up of at least about 95%, 98%, or 99% by weight of a preferred enantiomer. Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including high-pressure liquid chromatography (HPLC) on chiral support and the formation and crystallization of chiral salts or be prepared by asymmetric syntheses.
[0021] The expression "pharmaceutically acceptable salt" refers to those salts of the compounds of the present description which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). The salts can be prepared in situ during the final isolation and purification of the compounds of the present description, or separately by reacting a free base function of the compound with a suitable organic or inorganic acid (acid addition salts) or by reacting an acidic function of the compound with a suitable organic or inorganic base (base-addition salts).
[0022] The term “solvate” refers to a physical association of one of the present compounds with one or more solvent molecules, including water and non-aqueous solvent molecules. This physical association may include hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid. The term “solvate” encompasses both solution-phase and isolable solvates. Exemplary solvates include, without limitation, hydrates, hemihydrates, ethanolates, hemiethanolates, n-propanolates, iso-propanolates, 1 -butanolates, 2-butanolate, and solvates of other physiologically acceptable solvents, such as the Class 3 solvents described in the International Conference on Harmonization (ICH), Guide for Industry, Q3C Impurities: Residual Solvents (1997). Accordingly, the compound as herein described also includes each of its solvates and mixtures thereof.
[0023] The expression "pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds formed by the process of the present description which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit / risk ratio, and effective fortheir intended use. "Prodrug", as used herein means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to afford any compound delineated by the formulae of the instant description.
[0024] Abbreviations may also be used throughout the application, unless otherwise noted, such abbreviations are intended to have the meaning generally understood by the field. Examples of such abbreviations include Me (methyl), Et (ethyl), Pr (propyl), i-Pr (isopropyl), Bu (butyl), t-Bu (tert-butyl), i-Bu (iso-butyl), s-Bu (sec-butyl), c-Bu (cyclobutyl), Ph (phenyl), Bn (benzyl), Bz (benzoyl), CBz or Cbz or Z (carbobenzyloxy), Boc or BOC (tert-butoxycarbonyl), and Su or Sue (succinimide). For more certainty, additional definitions of specific abbreviations are also included in the introduction of the Examples section.
[0025] The number of carbon atoms in a hydrocarbyl substituent can be indicated by the prefix "Cx-Cy" or "Cx-y" where x is the minimum and y is the maximum number of carbon atoms in the substituent. However, when the prefix “Cx-Cy” or "Cx-y" is associated with a group incorporating one or more heteroatom(s) by definition (e.g. heterocycloalkyl, heteroaryl, etc), then x and y define respectively the minimum and maximum number of atoms in the cycle, including carbon atoms as well as heteroatom(s).
[0026] The term "alkyl" as used herein, refers to a saturated, straight- or branched-chain hydrocarbon radical typically containing from 1 to 20 carbon atoms. For example, "Ci-Cs alkyl" contains from one to eight carbon atoms. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, fert-butyl, neopentyl, n-hexyl, heptyl, octyl radicals and the like.
[0027] The term "alkenyl" as used herein, denotes a straight- or branched-chain hydrocarbon radical containing one or more double bonds and typically from 2 to 20 carbon atoms. For example, "C2-8 alkenyl" contains from two to eight carbon atoms. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, l-methyl-2-buten-l-yl, heptenyl, octenyl and the like.
[0028] The term "alkynyl" as used herein, denotes a straight- or branched-chain hydrocarbon radical containing one or more triple bonds and typically from 2 to 20 carbon atoms. For example, "C2-8 alkynyl" contains from two to eight carbon atoms. Representative alkynyl groups include, but are not limited to, for example, ethynyl,1-propynyl, 1-butynyl, heptynyl, octynyl and the like.
[0029] The terms “cycloalkyl”, “alicyclic”, “carbocycle”, “carbocyclic” and equivalent expressions refer to a group comprising a saturated or partially unsaturated (non-aromatic) carbocyclic ring in a monocyclic or polycyclic ring system, including spiro (sharing one atom), fused (sharing at least one bond) or bridged (sharing two or more bonds) carbocyclic ring systems, having from three to fifteen ring members. Examples of cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopenten-1-yl, cyclopenten-2-yl, cyclopenten-3-yl, cyclohexyl, cyclohexen-1-yl, cyclohexen-2-yl, cyclohexen-3-yl, cycloheptyl, bicyclo[4,3,0]nonanyl, norbornyl, bicyclo[1,1,1]pentane, spiro[3.3]heptane and the like. The term cycloalkyl includes both unsubstituted cycloalkyl groups and substituted cycloalkyl groups. The term “Cs-Cncycloalkyl” refers to a cycloalkyl group having from 3 to the indicated “n” number of carbon atoms in the ring structure. Unless the number of carbons is otherwise specified, “lower cycloalkyl” groups as herein used, have at least 3 and equal or less than 8 carbon atoms in their ring structure.
[0030] As used herein, the term "heteroatom" includes but is not limited to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.
[0031] As used herein, the terms "heterocycle", "heterocycloalkyl", "heterocyclyl", "heterocyclic radical", and "heterocyclic ring" are used interchangeably and refer to a chemically stable 3- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated orpartially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 1-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR (as in N-substituted pyrrolidinyl). A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a chemically stable structure and any of the ring atoms can be optionally substituted. Examples of heterocycloalkyl groups include, but are not limited to, 1,3-dioxolanyl, pyrrolidinyl, pyrrolidonyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrodithienyl, tetrahydrothienyl, thiomorpholino, thioxanyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1 ,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, 3-azabicyclo[3,1,0]hexanyl, 3-azabicyclo[4,1,0]heptanyl, quinolizinyl, quinuclidinyl, hexamethyleneimine, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, and the like. Heterocyclic groups also include groups in which a heterocyclic ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, chromenyl, phenanthridinyl, 2-azabicyclo[2.2.1]heptanyl, octahydroindolyl, benzodioxole,tetrahydroquinolinyl,H;N or H , where the radical or point of attachment is on the heterocyclyl ring. A heterocyclyl group may be mono- or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted. The term “Cs-nheterocycloalkyl” refers to a heterocycloalkyl group having from 3 to the indicated “n” number of atoms in the ring structure, including carbon atoms and heteroatoms.
[0032] As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond between ring atoms but is not aromatic. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation but is not intended to include aryl or heteroaryl moieties, as herein defined.
[0033] The term "aryl" used alone or as part of a larger moiety as in "aralkyl", "aralkoxy", "aryloxy", or "aryloxyalkyl", refers to aromatic groups having 4n+2 conjugated ir(pi) electrons, wherein n is an integer from 1 to 3, in a monocyclic moiety or a bicyclic or tricyclic fused ring system having a total of six to 15 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to seven ring members. The term "aryl" may be used interchangeably with the term "aryl ring". In certain embodiments of the present description, "aryl" refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, azulenyl, anthracyl and the like, which may bear one or more substituents. The term "aralkyl" or "arylalkyl" refers to an alkyl residue attached to an aryl ring. Examples of aralkyl include, but are not limited to, benzyl, phenethyl, and the like. Also included within the scope of the term “aryl”, as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, indenyl, phthalimidyl, naphthimidyl, fluorenyl, phenanthridinyl, or tetrahydronaphthyl, and the like. The term “Ce-naryl” refers to an aryl group having from 6 to the indicated “n” number of atoms in the ring structure.
[0034] The term "heteroaryl", used alone or as part of a larger moiety, e.g., "heteroaralkyl", or "heteroaralkoxy", refers to aromatic groups having 4n+2 conjugated ir(pi) electrons, wherein n is an integer from 1 to 3 (e.g. having 5 to 18 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 TT electrons shared in a cyclic array); and having, in addition to carbon atoms, from one to five heteroatoms. The term "heteroatom" includes but is not limited to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. A heteroaryl may be a single ring, or two or more fused rings. The term "heteroaryl", as used herein, also includes groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclic rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples of heteroaryl groups include thienyl, furanyl (furyl), pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, 3H-indolyl, isoindolyl, indolizinyl, benzothienyl (benzothiophenyl), benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, pyrrolopyridinyl (e.g. pyrrolo[3,2-b]pyridinyl or pyrrolo[3,2-c]pyridinyl), pyrazolopyridinyl (e.g. pyrazolo[1 ,5-a]pyridinyl), furopyridinyl, purinyl, imidazopyrazinyl (e.g. imidazo[4,5-b]pyrazinyl), quinolyl (quinolinyl), isoquinolyl (isoquinolinyl), quinolonyl, isoquinolonyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, naphthyridinyl, and pteridinyl carbazolyl, acridinyl, phenanthridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-l,4-oxazin-3(4H)-one. A heteroaryl group may be mono- or bicyclic. Heteroarylgroups include rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted. Examples include, but are not limited to, pyridinylmethyl, pyrimidinylethyl and the like. For instance, the term “Cs-nheteroaryl” refers to a heteroaryl group having from 5 to the indicated “n” number of atoms in the ring structure, including carbon atoms and heteroatoms.
[0035] As described herein, compounds of the present description may contain "optionally substituted" moieties. In general, the term "substituted", whether preceded by the term "optionally" or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at each position. Combinations of substituents envisioned under the present description are preferably those that result in the formation of chemically stable or chemically feasible compounds. The term "chemically stable", as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
[0036] The term “halo” designates a halogen atom, i.e. a fluorine, chlorine, bromine or iodine atom, preferably fluorine or chlorine.
[0037] The term "optionally substituted" refers to groups that are substituted or unsubstituted by independent replacement of one, two, or three or more of the hydrogen atoms thereon with substituents including, but not limited to F, Cl, Br, I, OH, CO2H, alkoxy, oxo, thiooxo, NO2, CN, CF3, NH2, NHalkyl, NHalkenyl, NHalkynyl, NHcycloalkyl, NHaryl, NHheteroaryl, NHheterocyclic, dialkylamino, diarylamino, diheteroarylamino, O-alkyl, O-alkenyl, O-alkynyl, O-cycloalkyl, O-aryl, O-heteroaryl, O-haloalkyl, O-heterocyclic, C(O)alkyl, C(O)alkenyl, C(O)alkynyl, C(O)cycloalkyl, C(O)aryl, C(O) heteroaryl, C(O)heterocycloalkyl, CO2alkyl, CO2alkenyl, CO2alkynyl, CO2cycloalkyl, CO2aryl, CO2heteroaryl, CO2heterocycloalkyl, OC(O)alkyl, OC(O)alkenyl, OC(O)alkynyl, OC(O)cycloalkyl, OC(O)aryl, OC(O)heteroaryl, OC(O)heterocycloalkyl, C(O)NH2, C(O)NHalkyl, C(O)NHalkenyl, C(O)NHalkynyl, C(O)NHcycloalkyl, C(O)NHaryl, C(O) NHheteroaryl, C(O)NHheterocycloalkyl, OCO2alkyl, OCO2alkenyl, OCO2alkynyl, OCO2cycloalkyl, OCO2aryl, OCO2heteroaryl, OCO2heterocycloalkyl, OC(O)NH2, OC(O)NHalkyl, OC(O)NHalkenyl, OC(O) NHalkynyl, OC(O)NHcycloalkyl, OC(O)NHaryl, OC(O) NHheteroaryl, OC(O)NHheterocycloalkyl, NHC(O)alkyl, NHC(O)alkenyl, NHC(O)alkynyl, NHC(O)cycloalkyl,NHC(O)aryl, NHC(O)heteroaryl, NHC(O)heterocycloalkyl, NHCO2alkyl, NHCO2alkenyl, NHCO2alkynyl, NHCO2cycloalkyl, NHCO2aryl, NHCO2heteroaryl, NHCO2heterocycloalkyl, NHC(O)NH2, NHC(O)NHalkyl, NHC(O)NHalkenyl, NHC(O)NHalkenyl, NHC(O)NHcycloalkyl, NHC(O)NHaryl, NHC(O)NHheteroaryl, NHC(O)NHheterocycloalkyl, NHC(S)NH2, NHC(S)NHalkyl, NHC(S)NHalkenyl, NHC(S)NHalkynyl, NHC(S)NHcycloalkyl, NHC(S)NHaryl, NHC(S)NHheteroaryl, NHC(S)NHheterocycloalkyl, NHC(NH)NH2, NHC(NH)NHalkyl, NHC(NH)NHalkenyl, NHC(NH)NHalkenyl, NHC(NH)NHcycloalkyl, NHC(NH)NHaryl, NHC(NH)NHheteroaryl, NHC(NH)NHheterocycloalkyl, NHC(NH)alkyl, NHC(NH)alkenyl, NHC(NH)alkenyl, NHC(NH)cycloalkyl, NHC(NH)aryl, NHC(NH)heteroaryl, NHC(NH)heterocycloalkyl, C(NH)NHalkyl, C(NH)NHalkenyl, C(NH)NHalkynyl, C(NH)NHcycloalkyl, C(NH)NHaryl, C(NH)NHheteroaryl, C(NH)NHheterocycloalkyl, S(O)alkyl, S(O)alkenyl, S(O)alkynyl, S(O)cycloalkyl, S(O)aryl, S(O)2alkyl, S(O)2alkenyl, S(O)2alkynyl, S(O)2cycloalkyl, S(O)2aryl, S(O)heteroaryl, S(O)heterocycloalkyl, SO2NH2, SO2NHalkyl, SO2NHalkenyl, SO2NHalkynyl, SO2NHcycloalkyl, SO2NHaryl, SO2NHheteroaryl, SO2NHheterocycloalkyl, NHSO2alkyl, NHSO2alkenyl, NHSO2alkynyl, NHSO2cycloalkyl, NHSO2aryl, NHSO2heteroaryl, NHSO2heterocycloalkyl, CH2NH2, CH2CN, CH2F, CH2OH, CH2OCH3, C(CH3)2OH, CH2SO2CH3, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, cycloalkyl, carbocyclic, heterocyclic, phenyl, phenol, polyalkoxyalkyl, polyalkoxy, methoxymethoxy, methoxyethoxy, SH, S-alkyl, S-alkenyl, S-alkynyl, S-cycloalkyl, S-aryl, S-heteroaryl, S-heterocycloalkyl, or methylthiomethyl.
[0038] The term “ring” as used herein, refers to a Cs-Cecycloalkyl, a 4- to 14-membered heterocycloalkyl, a Ce-C aryl, or a 5- to 10-membered heteroaryl.Compounds
[0039] The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. As such, the following embodiments are present alone or in combination if applicable.
[0040] The present compounds present a benzimidazole, and the likes, core structure to which is attached defined substituents to achieve the product’s beneficial activity. Examples of compounds as defined herein are illustrated by general Formula I:NHor a pharmaceutical acceptable salt, solvate, or prodrug thereof,wherein:X is selected from -CR2R2’-, -O- and -NR2-;XIis selected from -CR1R1’-, -O- and -NR1-;X3is selected from -O-, -NH- and -S-;X4is selected from -N=, -CH= and -CR7=;provided that when one of X and X1is -CR2R2’- or -CR1R1’-, then the other of X and X1is other than -CR2R2’- or-CR1R1’-, and provided that when one of X and X1is -O-, -NR1- or -NR2-, then the other of X and X1is other than -O-, -NR1- or -NR2-;Y1, Y2, Y3and Y4are independently selected from -N=, -CH= and -CR8=, and one of Y1, Y2, Y3_ Oand Y4is -C= to allow the connection w CZbJ) — \ith OH;R1, R1’, R2and R2’ are independently selected from -H, linear or branched Ci-Cealkyl, C3-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6, -S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear orbranched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’; or R1and R2are taken together with their adjacent atoms to form a ring, the ring being optionally substituted with one or more substituents; or R1and R1’ are taken together with their adjacent carbon atom to form a ring, the ring being optionally substituted with one or more substituents; or R2and R2’ are taken together with their adjacent carbon atom to form a ring, the ring being optionally substituted with one or more substituents; wherein the ring formed by R1and R2or by R1and R1’ or by R2and R2’ is preferably selected from optionally substituted Cs-Cscycloalkyl and 4- to 14-membered heterocycloalkyl groups;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;R7is a linear or branched Ci-Cealkyl;R8is selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6, -S(=O)2-R5, -NR4S(=O)2-R5and -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5-to 10-membered heteroaryl are optionally substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or-S(=O)2-NR6R6’;( A )' is selected from the group consisting of 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl each optionally linked to NH through a Ci-Csalkyl group, the 4- to 14-membered heterocycloalkyl, Ce-C aryl or 5- to 10-membered heteroaryl being optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -OR3, SFs, or -SR3, wherein the linear or branched Ci-Cealkyl and Cs-Cscycloalkyl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3; andC B )- is selected from the group consisting of linear or branched Ci-Cealkyl, C2-Csalkyne, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, the linear or branched Ci-Cealkyl, C2-Csalkyne, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl or 5- to 10-membered heteroaryl being optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -C(=O)OH, -OR3, -SFs, or -SR3, wherein the linear or branched Ci-Cealkyl and Cs-Cscycloalkyl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3.
[0041] In one embodiment, the compound is of formula (I’):NHX is selected from -CR2R2’-, -O- and -NR2-;XIis selected from -CR1R1’-, -O- and -NR1-;X3is selected from -O-, -NH- and -S-;X4is selected from -N=, -CH= and -CR7=;provided that when one of X and X1is -CR2R2’- or -CR1R1’-, then the other of X and X1is other than -CR2R2’- or-CR1R1’-, and provided that when one of X and X1is -O-, -NR1- or -NR2-, then the other of X and X1is other than -O-, -NR1- or -NR2-;Y1, Y2and Y4are independently selected from -N=, -CH= and -CR8=;R1, R1’, R2and R2’ are independently selected from -H, linear or branched Ci-Cealkyl, C3-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6, -S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’; or R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, the 4- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents; or R1and R1’ are taken together with their adjacent carbon atom to form a Cs-Cscycloalkyl, the Cs-Cscycloalkyl being optionally substituted with one or more substituents; or R2and R2’ are taken together with their adjacent carbon atom to form a Cs-Cscycloalkyl, the Cs-Cscycloalkyl being optionally substituted with one or more substituents;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10- membered heteroaryl, wherein the Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;R7is a linear or branched Ci-Cealkyl;R8is selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, - NHC(=O)R5, -C(=O)-NR6R6, -S(=O)2-R5, -NR4S(=O)2-R5and -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5-to 10-membered heteroaryl are optionally substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or-S(=O)2-NR6R6’;I A )' is selected from the group consisting of 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl each optionally linked to NH through a Ci-Cealkyl group, the 4- to 14-membered heterocycloalkyl, Ce-Cwaryl or 5- to 10-membered heteroaryl being optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce- Cwaryl, 5- to 10-membered heteroaryl, -OR3, SF5, or -SR3, wherein the linear or branched Ci- Cealkyl and Cs-Cscycloalkyl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3; andis selected from the group consisting of 4- to 14-membered heterocycloalkyl, Ce- Cwaryl and 5- to 10-membered heteroaryl, the 4- to 14-membered heterocycloalkyl, Ce-Cwaryl or 5- to 10-membered heteroaryl being optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, - OR3, SF5, or -SR3, wherein the linear or branched Ci-Cealkyl and Cs-Cscycloalkyl are optionallyfurther substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3.
[0042] In another embodiment,is a 4- to 14-membered heterocycloalkyl or Ce-Cwaryl optionally substituted with one or more substituents, the substituents being preferably selected from halogen, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -OR3or -SR3, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, thesubstituents being preferably selected from halogens or -CF3; andis optionally linked to NH through a Ci-Csalkyl group.
[0043] In another embodiment,is a 5-membered heteroaryl optionally substituted with one or more substituents, the substituents being preferably selected from halogen, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -OR3or -SR3, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, the substituents being preferably selected fromhalogens or -CF3;and is optionally linked to NH through a Ci-Csalkyl group.
[0044] In some instances,may be selected from:is optionally linked to NH through a Ci-Csalkyl group;wherein R9is independently in each occurrence selected from the group consisting of halogen, - OR3, SR3, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, preferably selected from halogens, -CF3, linear or branched Ci-Cealkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, and 5- to 10-membered heteroaryl, andR3is selected from the group consisting of -H, -CF3 and linear or branched Ci-Cealkyl optionally substituted with one or more substituents.optionally linked to NH through a Ci-Csalkyl group.is optionally linked to NH through a Ci-Csalkyl group;R9is independently in each occurrence selected from the group consisting of halogen, -OR3, -SR3, -SFs, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl and 5- to 10-membered heteroaryl, or two R9on adjacent atoms are taken together to form a Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl or 5- to 10-membered heteroaryl, wherein the Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents preferably selected from halogens, -CF3, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl; andR3is selected from the group consisting of -H and linear or branched Ci-Cealkyl optionally substituted with one or more substituents preferably selected from halogens.
[0047] In one embodiment, R9is independently selected from the group consisting of -Cl, -F, -CF3, -OCF3, -SCF3, -SFs, -OCH3, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, each optionally further substituted, preferably with one or more -CF3.
[0048] Non-limiting examples ofinclude the following groups:( B )
[0050] In some embodiments,- is selected from linear or branched Ci-Cealkyl, C3- Cscycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, the linear or branched Ci-Cealkyl, C3-Cscycloalkyl, Ce-C aryl or 5- to 10-membered heteroaryl being optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, and -OR3.
[0052] In some other instances, may be selected from:
[0053] In yet other instances,OH may be selected from:OH , or OH
[0054] In some embodiments, the compound is of Formula I’a:or a pharmaceutical acceptable salt, solvate, or prodrug thereof,wherein R1, R1’, X, X3, X4,Y1, Y2, Y4and are as defined herein.
[0055] In another embodiment, R1and R1’ are independently selected from -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6, -S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;or R1and R1’ are taken together with their adjacent carbon atom to form a Cs-Cscycloalkyl, the Cs-Cscycloalkyl being optionally substituted with one or more substituents.
[0056] In another embodiment, X is -O-.
[0057] In yet another embodiment, X is -NR2-.
[0058] In one embodiment, R2is selected from -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;or R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, the 4- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents.
[0059] In some embodiments, the compound is of Formula I’b: / X ON X XHR2R2x‘HO(I’b) or a pharmaceutical acceptable salt, solvate, or prodrug thereof,( A )Bwherein R2, R2’, X1, X3, X4,XX and are as defined herein.
[0060] In another embodiment, R2and R2’ are independently selected from -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6, -S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;or R2and R2’ are taken together with their adjacent carbon atom to form a Cs-Cscycloalkyl, the Cs-Cscycloalkyl being optionally substituted with one or more substituents.
[0061] In another embodiment, X1is -O-.
[0062] In yet another embodiment, X1is -NR1-.
[0063] In one embodiment, R1is selected from -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;or R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, the 4- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents.
[0064] In some embodiments, R1, R1’, R2and R2’ are independently selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl and Ce-Cwaryl, optionally substituted with one or more substituents, thesubstituents being preferably selected from -Cl, -F, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl and Ce-C aryl.
[0065] In some embodiments, R1, R1’, R2and R2’ are independently selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -CH2CF2CH3, cyclopropyl, cyclopentyl, cyclohexyl,phenyl,and
[0066] In some embodiments, R1is -CH3 and R1’ is -H or -CH3.
[0067] In some embodiments, R2is -CH3 and R2’ is -H or -CH3.
[0068] In some embodiments, R1and R1’ are taken together with their adjacent carbon to form a cyclopropyl.
[0069] In another embodiment, R2and R2’ are taken together with their adjacent carbon to form a cyclopropyl.
[0070] In yet another embodiment, R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, the 4- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents.
[0071] In one embodiment, R1and R2are taken together with their adjacent atoms to form a 6-to 14-membered heterocycloalkyl, the 6- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents.
[0072] In some instances, the 6- to 14-membered heterocycloalkyl may be selected from:,or ' / vv; whereinq is between 1 and 2; andX5is -CH2-, -NR11-, -S- or-O-;R11is selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4-to 14-membered heterocycloalkyl and Ce-C aryl, optionally substituted with one or more substituents; andwherein the 6- to 14-membered heterocycloalkyl is optionally further substituted with one or more substituents.
[0073] In one embodiment, the 6- to 14-membered heterocycloalkyl is of formula:, wherein q and X5are as previously defined, and is optionally further substituted with one or more substituents.
[0074] In one preferred embodiment, q is 1. Alternatively, q is 2.
[0075] In another preferred embodiment, X5is -CH2-. Alternatively, X5is -O-.
[0076] In another embodiment, R1and R2are taken together with their adjacent atoms to form a 4- or 5-membered heterocycloalkyl, the 4- or 5-membered heterocycloalkyl being optionally substituted with one or more substituents.
[0077] In one preferred embodiment, 4- or 5-membered heterocycloalkyl is a 5-membered heterocycloalkyl, optionally substituted with one or more substituents.
[0078] In some instances, the 5-membered heterocycloalkyl is of formula:
[0079] In some embodiment, the heterocycloalkyl is substituted with one or more R10substituents independently in each occurrence selected from the group consisting of halogen, -CN, OR3, SR3, -NR4R4’, -NR4C(=O)R5, -C(=O)-NR6R6’, =0 (oxo), -S(=O)2-R5, -NR4S(=O)2R5, -S(=O)2-NR6R6’, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, or two R10are taken together with their adjacent carbon atom(s) to form a fused, spiro or bridged Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl or 5- to 10-membered heteroaryl, wherein the Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents preferably selected from halogens, -CN, OR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -CF3, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, wherein R3, R4, R4’, R5, R6and R6’ are previously defined.
[0080] In another embodiment, the heterocycloalkyl is unsubstituted.
[0081] In one preferred embodiment, X3is -S-. Alternatively, X3is -NH- or -O-.
[0082] In another preferred embodiment, X4is -N=. Alternatively, X4is -CH=.
[0083] In yet another preferred embodiment, Y1is -N=, Y2is -CH= and Y3is -CH=. Alternatively, Y1is -CH=, Y2is -N= and Y3is -CH= or Y1is -CH=, Y2is -CH= and Y3is -N=.
[0084] Exemplary compounds as defined herein include each single compound described in the present application, including Compounds 1 to 50 in Table 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof.
[0085] Table 1: Compounds 1 to 50CLs\^T N— / HN ^O HN" T)X— \-"\F F? ULF^yo UCF^yo I FF H0T y HO Compound 7 Compound 8 / — \ H HT N — \ JHN^O / ? CWXl\\ \=^J ^ °Hoy y0H| I T QAFSF5Compound 9 Compound 10HF0:C^FNH UyOH 0^X10LNH MyOH F yyLSF5°F yALcF30Compound 11 Compound 12 H H CWYl 0^X1O-LNH MyOH0LNH L^OH FF0F yyLcF30CF3Cl Compound 13 Compound 14Compound 16Compound 17Compound 20Compound 21 Compound 22Hcw xi cWrCUx WHNUy™0 Q CF3Compound 23 Compound 24°^T ^ OH U*Y°H Q f Xs~ / L01 0Cl Cl Compound 25 Compound 26 H CWYl cw:CUx0^NH MyOH d^T U*Y°H O0CF3Compound 27 Compound 28Hcw Nx^XixXQ^NH U^OH d^T U*Y°H c l000FCF3CF3Compound 29 Compound 30or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
[0086] Examples of preferred compounds include, namely, Compounds 1(a), 8(lsomer 2), and 50(lsomer2) as defined herein, or a salt, solvate and / or prodrug thereof.
[0087] The present technology also covers isomers of the compounds as defined herein. For instance, isomers of the Compounds are identified using a letter after the compound number. Isomers of the above compounds include, for example, Compounds 1(a), 2(a), 3(a), 4(a), 5(a), 6(a), 7(a), 8(a) and 9(a) as defined in the Examples section, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
[0088] It is understood that any of the above compounds may be in any amorphous, crystalline or polymorphic form, including any salt or solvate form, or a mixture thereof. The compounds of the present description may be further modified by appending various functionalities via any synthetic means delineated herein to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
[0089] These compounds may be prepared by conventional chemical synthesis, such as those exemplified in the Schemes and Examples of the present disclosure. As can be appreciated bythe skilled artisan, further methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds.Methods, Uses, Formulations and Administration
[0090] As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in treatment, healing, prevention, or amelioration of a disease, disorder, or symptom thereof, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.
[0091] As used herein, the terms "treatment," "treat," and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
[0092] According to one embodiment, the condition, disease or disorder is characterized by dysregulation of the glucose-dependent insulinotropic polypeptide receptor (GIPR).
[0093] For example, the condition, disease or disorder is selected from metabolic diseases and obesity.
[0094] In one embodiment, the condition, disease or condition to be treated is a GIPR-related condition, disease, or disorder. The GIPR-related condition, disease, or disorder includes one selected from diabetes [e.g. Type 1 diabetes mellitus (T1D), Type 2 diabetes mellitus (T2DM), including pre-diabetes], idiopathic T1D (Type 1b), latent autoimmune diabetes in adults (L DA), early-onset T2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabeticnephropathy, kidney disease [e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, or chronic kidney disease (CKD)], diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea [e.g. obstructive sleep apnea (OSA)], obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urine incontinence), eating disorders (including binge eating syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndromes), weight gain such as weight gain caused by use of other agents (e.g., caused by use of steroids and / or antipsychotics, or caused by treatment of depression, or caused by use of agents on cognitive function), excessive sugar craving, dyslipidemia [including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high LDL (low-density lipoprotein) cholesterol, and low HDL (high-density lipoprotein) cholesterol], hyperinsulinemia, nonalcoholic fatty liver disease [NAFLD, including related diseases such as steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma], cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, heart failure [e.g. congestive heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF)], myocardial infarction (e.g. necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, osteoarthritis, Parkinson’s disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, polycystic ovary syndrome (PCOS), and addiction (e.g., addiction to alcohol, nicotine, and / or drug).
[0095] The term "patient or subject" as used herein refers to an animal such as a mammal. A subject may therefore refer to, for example, mice, rats, dogs, cats, horses, cows, pigs, guinea pigs, primates including humans and the like. Preferably the subject is a human.
[0096] The present description therefore further relates to a method of treating or preventing metabolic diseases or diabetes in a subject, such as a human subject. The method comprisesadministering a therapeutically effective amount of a GIPR antagonist, such as a compound as defined herein, to a subject in need of such treatment.
[0097] In another embodiment, the present description further relates to a method of treating or preventing a condition, a disease, or a disorder for which modulation of the glucose-dependent insulinotropic polypeptide receptor (GIPR) is indicated. The method comprises administering a therapeutically effective amount of a GIPR antagonist, such as a compound as defined herein, to a subject in need of such treatment.
[0098] In another embodiment, the present description further relates to a method of treating or preventing a condition, a disease, or a disorder for use in the treatment or prevention of a condition, a disease or a disorder selected from diabetes (e.g. Type 1 diabetes mellitus (T1D), Type 2 diabetes mellitus (T2DM), including pre-diabetes), idiopathic T1D (Type 1b), latent autoimmune diabetes in adults (LADA), early-onset T2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, or chronic kidney disease (CKD)), diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea (e.g. obstructive sleep apnea (OSA)), obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urine incontinence), eating disorders (including binge eating syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndromes), weight gain such as weight gain caused by use of other agents (e.g., caused by use of steroids and / or antipsychotics, or caused by treatment of depression, or caused by use of agents on cognitive function), excessive sugar craving, dyslipidemia [including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high LDL (low-density lipoprotein) cholesterol, and low HDL (high-density lipoprotein) cholesterol], hyperinsulinemia, nonalcoholic fatty liver disease [NAFLD, including related diseases such as steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma], cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, heart failure (e.g. congestive heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF)), myocardial infarction (e.g. necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis,arthritis, osteoporosis, osteoarthritis, Parkinson’s disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, polycystic ovary syndrome (PCOS), and addiction (e.g., addiction to alcohol, nicotine, and / or drug). The method comprises administering a therapeutically effective amount of a GIPR antagonist, such as a compound as defined herein, to a subject in need of such treatment.
[0099] In certain embodiments, the present description provides a method of treating a disorder (as described herein) in a subject, comprising administering to the subject identified as in need thereof, GIPR antagonist, such as a compound of the present description. The identification of those patients who are in need of treatment for the disorders described above is well within the ability and knowledge of one skilled in the art. Certain of the methods for identification of patients which are at risk of developing the above disorders which can be treated by the subject method are appreciated in the medical arts, such as family history, and the presence of risk factors associated with the development of that disease state in the subject patient. A clinician skilled in the art can readily identify such candidate patients, by the use of, for example, clinical tests, physical examination, medical / family history, and genetic determination.
[0100] A method of assessing the efficacy of a treatment in a subject includes determining the pre-treatment symptoms of a disorder by methods well known in the art and then administering a therapeutically effective amount of a compound of the present description, to the subject. After an appropriate period of time following the administration of the compound (e.g., 1 week, 2 weeks, one month, six months), the symptoms of the disorder are determined again. The modulation (e.g., decrease) of symptoms and / or of a biomarker of the disorder indicates efficacy of the treatment. The symptoms and / or biomarker of the disorder may be determined periodically throughout treatment. For example, the symptoms and / or biomarker of the disorder may be checked every few days, weeks or months to assess the further efficacy of the treatment. A decrease in symptoms and / or biomarker of the disorder indicates that the treatment is efficacious.
[0101] In some embodiments, the therapeutically effective amount of a GIPR antagonist, such as a compound as defined herein, can be administered to a patient alone or in a composition, admixed with a pharmaceutically acceptable carrier, adjuvant, or vehicle.
[0102] The expression "pharmaceutically acceptable carrier, adjuvant, or vehicle" and equivalent expressions, refer to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this disclosure include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
[0103] Compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Other modes of administration also include intradermal or transdermal administration.
[0104] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, surfactants, sweetening, flavoring, and perfuming agents.
[0105] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectablesolution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, ll.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
[0106] Injectable formulations can be sterilized, for example, by filtration through a bacterial -retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0107] In order to prolong the effect of a provided compound, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled.
[0108] Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
[0109] Compositions for rectal administration are preferably suppositories which can be prepared by mixing the compounds of the present description with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum and release the active compound.
[0110] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin,polyvinylpyrrolidinone (PVP), sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[0111] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[0112] The composition can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
[0113] Dosage forms for topical or transdermal administration of a compound of the present description include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalantsor patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of the present description. Additionally, the description contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
[0114] Pharmaceutically acceptable compositions provided herein may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promotors to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.
[0115] Pharmaceutically acceptable compositions provided herein may be formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this disclosure are administered without food. In other embodiments, pharmaceutically acceptable compositions of this disclosure are administered with food.
[0116] The amount of compound that may be combined with carrier materials to produce a composition in a single dosage form will vary depending upon the patient to be treated and the particular mode of administration. Provided compositions may be formulated such that a dosage of between 0.01 - 100 mg / kg body weight / day of the inhibitor can be administered to a patient receiving these compositions.
[0117] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the judgment of the treating physician, and the severity of the symptoms associated with the proliferative disease or disorder. The amount of a provided compound in the composition will also depend upon the particular compound in the composition.
[0118] Compounds or compositions described herein may be administered using any amount and any route of administration effective for treating or lessening the severity of the symptoms ascontemplated herein. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. Provided compounds are preferably formulated in unit dosage form for ease of administration and uniformity of dosage. The expression "unit dosage form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present disclosure will be decided by the attending physician within the scope of sound medical judgment.
[0119] Pharmaceutically acceptable compositions of this disclosure can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, provided compounds may be administered orally or parenterally at dosage levels of about 0.01 mg / kg to about 50 mg / kg and preferably from about 1 mg / kg to about 25 mg / kg of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
[0120] It will be understood that the total daily usage of the compounds and compositions of the present description will be decided by the attending physician within the scope of sound medical judgment. The total daily inhibiting dose of the compound of the present description administered to a subject in single or in divided doses can be in amounts, for example, from 0.01 to 50 mg / kg body weight or more usually from 0.1 to 25 mg / kg body weight. Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose. In one embodiment, treatment regimens according to the present description comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of the present description per day in single or multiple doses.
[0121] Depending upon the condition, disease or disorder to be treated, additional therapeutic agents may also be present in the compositions of this disclosure or administered separately as part of a dosage regimen, e.g. an additional incretin modulator. Non-limiting examples of additional therapeutic agents which could be used in combination with the present compounds include: semaglutide, liraglutide, danuglipron or orforglipron.
[0122] The recitation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.EXAMPLES
[0123] The following non-limiting examples are illustrative embodiments and should not be construed as further limiting the scope of the present invention.General Methods:
[0124] The Examples set forth herein below provide syntheses and experimental results obtained for certain exemplary compounds. As it is well known to a person skilled in the art, reactions are performed in an inert atmosphere (nitrogen or argon) where necessary to protect reaction components from air and moisture. Temperatures are given in degrees Celsius (°C). Solution percentages and ratios express a volume-to-volume relationship, unless otherwise stated. The reactants used in the examples below may be obtained either as described herein, or if not described herein, are themselves either commercially available or may be prepared from commercially available materials by methods known in the art.
[0125] All chemicals were of the highest purity and commercially available ones were used without further purification. Purification by column chromatography was performed with silica gel on CombiFlash and Teledyne-lsco with solvent mixtures specified for each compound where applicable. Purification by preparative HPLC were performed on Agilent system with an elution phase of methanol, water and 0.1% formic acid or NH4OAC when specified. NMR spectra were recorded using Varian or Bruker 400 MHz spectrometer. Chemical shifts are reported as parts per million and referenced according to the residual solvent peak and coupling constants (J) are reported in hertz (Hz). LCMS data were acquired on a Shimadzu LCMS-2020 with electrospray ionization in positive / negative ion detection mode with 20ADXR pump, SIL-20ACXR autosampler, LCMS 2020 MS detector, Alltech ELSD 3300HP detector, (CTO-40C column oven and SPD-M40 PDA detector) or (CTO-20AC column oven and SPD-M20A PDA detector), Shim pack Scepter C18-120 columns, (Kinetex EVO C18 columns or XSelect HSS T3 columns or HALO 90A C18 columns), acetonitrile / water gradients, and either trifluoroacetic acid, formic acid, or ammonium bicarbonate modifiers. All new compounds have been characterized by1H NMR, LCMS and / or HRMS.
[0126] Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, concentrations, properties, stabilities, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” At the very least, each numerical parameter should at least be construed in light of the number of reported significantdigits and by applying ordinary rounding techniques. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the present specification and attached claims are approximations that may vary depending upon the properties sought to be obtained. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the embodiments are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors resulting from variations in experiments, testing measurements, statistical analyses and such.
[0127] Abbreviations:ACN Acetonitrileaq AqueousBoc terf-butyloxycarbonylBSA Bovin serum albumin°C Degrees CelsiuscAMP Cyclic adenosine monophosphoateCAN Ammonium cerium(IV) nitrated Doubletdd Doublet of doubletsdt Doublets of tripletsDCM DichloromethaneDIEA N,N-DiisopropylethylamineDMSO Dimethylsulfoxide5 Chemical shiftEA Ethyl acetateEC50 Drug concentration that gives 50% of EmaxEC80 Drug concentration that gives 80% of EmaxEDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimideEquiv. Equivalent(s)Emax Maximal signal obtained by an appropriate agonistES ElectrosprayEu-cAMP Europium-labeled antibody paired with a cAMP analogFA Formic acidGIP Glucose-dependent insulinotropic polypeptideGIPR Glucose-dependent insulinotropic polypeptide receptor HATU Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium HBSS Hanks Buffered Salt SolutionHEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) HCI Hydrochloric acidHz HertzIBMX 3-isobutyl-1 -methylxanthineIC50 Half maximal inhibitory concentrationJ Coupling constantAex Excitation wavelengthAem Emission wavelengthLCMS Liquid chromatography coupled with mass spectrometry m Multipletmg Milligramsmin MinutesmL MillilitermM Millimolar (mmol / L)mmol MillimolesMeCN Acetonitrilem / z Mass to charge rationm NanometersNMM N-methylmorpholine1H NMR Proton nuclear magnetic resonancePE Petroleum etherPPm Parts per millionPrep-HPLC Preparative high-performance liquid chromatography q Quartetrpm Revolutions per minuteRT Room temperature or Retention times Singlett TripletTHF TetrahydrofuranTR-FRET Time-resolved fluorescence energy transferpL MicroliterUV UltravioletVol. VolumeExample 1: General Procedures:
[0128] All compounds as herein defined were prepared according to methods as indicated below. Characterization data by mass spectrometry and NMR are provided for each of the compounds when available. The compounds are tested in the assays described in Example 3.Synthetic route 1 (Scheme 1):Scheme 1
[0129] If isocyanates or imidazoureas (lnt-1) are not commercially available, they can be formed by reacting appropriate aryl / heteroaryl amines respectively with triphosgene or carbodiimidazole. Protected aminoacid (Jnt-2) are then coupled with isocyanates or imidazoureas lnt-1) to yield ureas (lnt-3). Subsequent ester hydrolysis then yields carboxylic acids (lnt-4). Condensation with 1 ,2-dianilines then affords halogenated benzimidazoles (lnt-5) where X = halogen. Cross-coupling with a coupling partner then affords Compounds 1, 2 and 9.Synthetic route 2 (Scheme 2):I nt- 1 EDCIScheme 2
[0130] If isocyanates or imidazoureas (lnt-1) are not commercially available, they can be formed by reacting appropriate aryl / heteroaryl amines respectively with triphosgene or carbodiimidazole. Protected aminoacid (Jnt-2) are then condensed with 1 ,2-dianilines to afford protected halogenated benzimidazoles (lnt-3) where X = halogen. Deprotection then yields halogenated benzimidazoles (Jnt-4). Coupling with isocyanates or imidazoureas lnt-1) then yield ureas (Jnt-5). Subsequent cross-coupling with a coupling partner then affords Compounds 3 to 7.Example 2: Synthetic procedures(i) (R)-4-(2-(1-((4-isopropylphenyl)carbamoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-5-yl)benzoic acid (Compound 1(a))
[0131] Step 1: To a stirred solution of commercially available ((4-isopropylphenyl)carbamoyl)-D-proline (500 mg, 1.81 mmol, 1.00 equiv) and HATLI (1030 mg, 2.71 mmol, 1.50 equiv) in THF (5mL) were added 4-bromobenzene-1,2-diamine (338 mg, 1.81 mmol, 1.00 equiv) and DIEA (584 mg, 4.52 mmol, 2.50 equiv) at room temperature. The resulting mixture was stirred at room temperature for 3 hours. The resulting mixture was poured into water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (1x20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. To a stirred solution of crude product was added AcOH (10 mL) at room temperature. The resulting mixture was stirred at 60°C for 3 hours. The resulting mixture was concentrated under vacuum. The mixture was basified to pH 7 with saturated NaHCCh (aq.). The resulting mixture was poured into water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (1x 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE I EA (1:2) to afford (R)-2-(5-bromo-1H-benzo[d]imidazol-2-yl)-N-(4-isopropylphenyl)pyrrolidine-1 -carboxamide (600 mg, 78% yield, 92% purity) as a light pink solid. LCMS (ES, m / z): 427.1 [M+H]+.
[0132] Step 2: To a stirred solution of (R)-2-(5-bromo-1H-benzo[d]imidazol-2-yl)-N-(4-isopropylphenyl)pyrrolidine-1 -carboxamide (350 mg, 0.819 mmol, 1 equiv) and 4-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (243 mg, 0.979 mmol, 1.20 equiv) in 1,4-dioxane (4 mL) and H2O (0.8 mL) were added Pd(dppf)Ch (119 mg, 0.163 mmol, 0.20 equiv) and K2CO3 (226 mg, 1.635 mmol, 2.00 equiv) at room temperature. The resulting mixture was stirred at 80°C for 2 hours under nitrogen atmosphere. The resulting mixture was concentrated under vacuum and the residue was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 10% to 50% gradient in 10 min; detector, UV 254 nm. The crude product was purified by Prep-HPLC with the following conditions (Column: XBridge Prep OBD C18 Column30*150 mm; Mobile Phase A: Water(10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 5% B to 5% B in 2 min, 19% B to 39% B in 10 min; Wave Length: 254 / 220 nm; RT1(min): 9.8) to afford (R)-4-(2-(1-((4-isopropylphenyl)carbamoyl)pyrrolidin-2-yl)-1 H-benzo[d]imidazol-5-yl)benzoic acid (Compound 1(a), 26.8 mg, 7% yield, 98% purity) as an off-white solid.
[0133] LCMS (ES, m / z): 469.25 [M+H]+.1H NMR (400 MHz, DMSO-cfe) 68.35 (s, 1H), 8.02 (d, J = 8.0 Hz, 2H), 7.87 - 7.70 (m, 3H), 7.62 - 7.46 (m, 2H), 7.41 (d, J = 8.2 Hz, 2H), 7.08 (d, J = 8.2 Hz, 2H), 5.35 - 5.15 (m, 1H), 3.78 (d, J = 8.4 Hz, 1H), 3.55 (d, J = 8.4 Hz, 1H), 2.86 - 2.73 (m, 1H), 2.38 -2.26 (m, 1H), 2.20 - 1.97 (m, 3H), 1.15 (d, J= 6.8 Hz, 6H).(ii) (R)-4-(2-(1 -((4-cyclopropyl-3-(trifluoromethyl)phenyl)carbamoyl)pyrrolidin-2-yl)- 1 H-benzo[d]imidazol-5-yl)benzoic acid (Compound 2(a))H
[0134] Step 1: To a stirred solution of 4-cyclopropyl-3-(trifluoromethyl)aniline (5.0 g, 25 mmol, 1.0 equiv) in DCM (50 mL) and NaHCCh (50 mL) were added triphosgene (2.22 g, 7.41 mmol, 0.300 equiv) in DCM (5 mL) dropwise at 0 °C. The resulting mixture was stirred at 0 °C for 30 min. The organic layer was collected, dried over Na2SO4 and filtered. The filtrate was concentrated under vacuum. The residue was used directly in the next step without further purification. LCMS (ES, m / z): 228.1 [M+H]+.
[0135] Step 2: To a stirred solution of D-proline (2.5 g, 22 mmol, 1.0 equiv) in THF (50 mL) were added NMM (4.50 g, 44.5 mmol, 2.00 equiv) and 1-cyclopropyl-4-isocyanato-2-(trifluoromethyl)benzene (5.0 g, 22 mmol, 1.0 equiv) in THF (50 mL) dropwise at 0 °C. The resulting mixture was stirred at room temperature for 1 hour. The resulting mixture was diluted with water (100 mL). The resulting mixture was washed with 2-methoxy-2-methylpropane (2 x 100 mL). The mixture was acidified to pH 2 with cone. HCI and the desired product extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with water (1 x 50 mL) and brine (1 x 50 mL), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This resulted in (2R)-1-{[4-cyclopropyl-3-(trifluoromethyl)phenyl]carbamoyl} pyrrolidine-2-carboxylic acid (4 g, 90% purity) as a white solid. LCMS (ES, m / z): 343.1 [M+H]+.
[0136] Step 3: To a stirred solution of ((4-cyclopropyl-3-(trifluoromethyl)phenyl)carbamoyl)-D-proline (150 mg, 0.438 mmol, 1.00 equiv) in THF (3 mL) were added HATU (250 mg, 0.657 mmol, 1.50 equiv), NMM (111 mg, 1.10 mmol, 2.50 equiv) and 4-bromobenzene-1,2-diamine (82 mg, 0.44 mmol, 1.0 equiv) portionwise at room temperature. The resulting mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure, then the residue was dissolved in AcOH (3 mL), and finally the resulting solution was stirred at 70°C for 4 hours. The resulting mixture was concentrated under reduced pressure, then the residue was diluted with water (50 mL), and finally the mixture was basified to pH 8 with sat. NaHCOs (aq).The resulting mixture was extracted with EtOAc (3 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford (R)-2-(5-bromo-1 H-benzo[d]imidazol-2-yl)-N-(4-cyclopropyl-3- (trifluoromethyl)phenyl)pyrrolidine-1 -carboxamide (100 mg, 46% yield, 92% purity) as a white solid. LCMS (ES, m / z): 493.1 [M+H]+.
[0137] Step 4: To a stirred solution of (R)-2-(5-bromo-1H-benzo[d]imidazol-2-yl)-N-(4-cyclopropyl-3-(trifluoromethyl)phenyl)pyrrolidine-1 -carboxamide (90 mg, 0.18 mmol, 1.0 equiv) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (54 mg, 0.22 mmol, 1.2 equiv) in 1,4-dioxane (4.5 mL) and H2O (0.9 mL) were added Pd(dppf)CI2(15 mg, 0.020 mmol, 0.11 equiv) and K2CC>3 (50 mg, 0.36 mmol, 2.0 equiv) at room temperature, and then the resulting mixture was stirred at 90°C for 1 hour under an atmosphere of nitrogen. The resulting mixture was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 10% to 30% gradient in 20 min; detector, UV 254 nm to afford (R)-4-(2-(1-((4-cyclopropyl-3-(trifluoromethyl)phenyl)carbamoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-5-yl)benzoic acid (Compound 2(a), 18.6 mg, 19% yield, 99.6% purity) as a white solid.
[0138] LCMS (ES, m / z): 535.2 [M+H]+;1H NMR (400 MHz, DMSO-cfe) 6 12.98 (s, 1H), 8.94 (s, 1 H), 7.95 - 7.91 (m, 3H), 7.68 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 8.4Hz, 2H), 7.43 (d, J = 8.0Hz, 2H), 7.03 (d, J = 8.4 Hz, 1H), 5.29-5.27 (m, 1H), 3.92- 3.84 (m, 1H), 3.57- 3.54 (m, 1H), 2.32 - 2.29 (m, 1H), 2.12 - 2.00 (m, 4H), 0.94 - 0.90 (m, 2H), 0.71 - 0.68 (m, 2H).(Hi) (R)-4-(2-(1-(3-(4-cyclopropyl-3-(trifluoromethyl)phenyl)-1-methylureido)ethyl)-1H-benzo[d]imidazol-5-yl)benzoic acid (Compound 3(a))
[0139] Compound 3(a) was made according to the General Procedures shown in Scheme 2.
[0140] LCMS (ES, m / z): 523.2 [M+H]+.1H NMR (400 MHz, DMSO-cfe) 6 12.46 (s, 1H), 8.71 (s, 1H), 8.02 - 7.95 (m, 3H), 7.81-7.74 (m, 4H), 7.55-7.51 (m, 1H), 7.09 (d, J = 8.8 Hz, 1H), 5.81-5.79 (m, 1H), 2.84 (s, 3H), 2.10-2.00 (m, 1H), 1.62 (d, J = 6.8 Hz, 3H), 0.98-0.95 (m, 2H), 0.74 - 0.72 (m, 2H).(iv) (R)-4-(2-(1-(((4-cyclopropyl-3-(trifluoromethyl)phenyl)carbamoyl)oxy)ethyl)-1H-benzo[d]imidazol-5-yl)benzoic acid (Compound 4(a))
[0141] Compound 4(a) was made according to the General Procedures shown in Scheme 2.
[0142] LCMS (ES, m / z): 510.1[M+H]+;1H NMR (400 MHz, DMSO-cfe) 6 12.73 (s, 2H), 10.13 (s, 1H), 8.04 -7.81 (m, 6H), 7.68- 7.57 (m, 3H), 7.12 (d, J= 8.4 Hz, 1H), 6.06 -6.01 (m, 1H), 2.10-2.03 (m, 1 H), 1.75 (d, J = 6.8 Hz, 3H), 0.99 - 0.95 (m, 2H), 0.75 - 0.71 (m, 2H).(v) (R)-4-(2-(1-((5-isopropylthiazol-2-yl)carbamoyl)pyrrolidin-2-yl)- 1 H-benzo[d]imidazo le-5-yl)benzoic acid (Compound 5(a))
[0143] Compound 5(a) is prepared according to the General Procedures shown in Scheme 2 using N-(5-isopropylthiazol-2-yl)-1H-imidazole-1-carboxamide as lnt-1 and (((9H-fluoren-9-yl)methoxy)carbonyl)-D-proline as lnt-2, 4-bromobenzene-1,2-diamine as the 1 ,2-dianiline and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate as the coupling partner, then hydrolysis of the tert-butyl ester.
[0144] LCMS (ES, m / z):476.2 [M+H]+;1H NMR (400 MHz, DMSO-cfe) 6 12.38 (s, 1H), 8.02 (d, J = 8.0 Hz, 2H), 7.93 - 7.70 (m, 3H), 7.66 - 7.53 (m, 2H), 7.00 (s, 1H), 5.30-5.21 (m, 1H), 3.79-3.71 (m, 1 H), 3.60 -3.56 (m, 1 H), 3.03-2.97 (m, 1 H), 2.32 -2.30 (m, 1 H), 2.21 - 1.87 (m, 3H), 1.21 (d, J= 6.8 Hz, 6H).(vi) (R)-4-(2-(1-((4-cyclopropyl-3-(trifluoromethyl)phenyl)carbamoyl)piperidin-2-yl)-1H-benzo[d]imidazol-5-yl)benzoic acid (Compound 6(a))
[0145] Compound 6(a) is prepared according to the General Procedures shown in Scheme 2 using 1-cyclopropyl-4-isocyanato-2-(trifluoromethyl)benzene as lnt-1 and (R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)piperidine-2-carboxylic acid as lnt-2, 4-bromobenzene-1,2-diamine as the 1 ,2-dianiline and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate as the coupling partner.(vii) (R)-4-(2-(2-((4-cyclopropyl-3-(trifluoromethyl)phenyl)carbamoyl)pyrrolidin-1-yl)-1H-benzo[d]imidazol-5-yl)benzoic acid (Compound 7(a))
[0146] Compound 7(a) is prepared according to Scheme 3.Synthetic route 3 (Scheme 3):(viii) (R)-4-(2-(1-((4-cyclopropyl-3-(trifluoromethyl)phenyl)carbamoyl)pyrrolidin-2-yl)benzo[d]thiazol-5-yl)benzoic acid (Compound 8(a)) and (S)-4-(2-(1-((4-cyclopropyl-3- (trifluoromethyl)phenyl)carbamoyl)pyrrolidin-2-yl)benzo[d]thiazol-5-yl)benzoic acid (Compound 8(b))8(a)
[0147] Compounds 8(a) and 8(b) are prepared according to Scheme 4.Synthetic route 4 (Scheme 4):Lawesson's reagent EDCI.DCM dioxane Fmo step 1 step 2c BrCAN, NaHCO3, MeCN DMF, piperidine step 3 step 4Pd(dppf)CI2,K2CO3dioxane, H2O step 6
[0148] Step 1: To a stirred solution of (((9H-fluoren-9-yl)methoxy)carbonyl)-D-proline (1.0 g, 3.0 mmol, 1.0 equiv) and 3-bromoaniline (510 mg, 2.97 mmol, 1.0 equiv) in DCM (10 mL) was added EDCI (0.85 g, 5.5 mmol, 1.9 equiv) at room temperature. The resulting mixture was stirred at room temperature for 1 hour. The resulting mixture was diluted with water (100 mL), extracted withCH2CI2 (3 x 100 mL). The combined organic layers were washed with brine (2 x 40 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE I EA (1:1) to afford (9H-fluoren-9-yl)methyl (R)-2-((3-bromophenyl)carbamoyl)pyrrolidine-1 -carboxylate (1.1 g, 75.5% yield, 95% purity) as a white solid. LCMS (ES, m / z):491.3[M+H]+.
[0149] Step 2: To a stirred solution of (9H-fluoren-9-yl)methyl (R)-2-((3-bromophenyl)carbamoyl)pyrrolidine-1 -carboxylate (1.0 g, 2.0 mmol, 1.0 equiv) in dioxane (10 mL) was added Lawesson's reagent (1.20 g, 2.97 mmol, 1.46 equiv) at room temperature. The resulting mixture was stirred at 110°C for 1 hour under nitrogen atmosphere. The resulting mixture was diluted with water (100 mL), extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 40 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE I EA (3:1) to afford (9H-fluoren-9-yl)methyl rac-2-((3-bromophenyl)carbamothioyl)pyrrolidine-1-carboxylate (850 mg, 82.3% yield, 80% purity) as a light brown oil. LCMS (ES, m / z): 507.1 [M+H]+.
[0150] Step 3: To a stirred solution of (9H-fluoren-9-yl)methyl rac-2-((3-bromophenyl)carbamothioyl)pyrrolidine-1-carboxylate (850 mg, 1.68 mmol, 1.00 equiv) and ammonium cerium(IV) nitrate (1.84 g, 3.35 mmol, 2.00 equiv) in MeCN (45 mL) was added NaHCOs (564 mg, 6.71 mmol, 4.01 equiv) at room temperature. The resulting mixture was stirred at 80°C for 1 hour under nitrogen atmosphere. The resulting mixture was diluted with water (100 mL). The resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 40 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 60% to 80% gradient in 20 min; detector, UV 254 nm. This resulted in (9H-fluoren-9-yl)methyl rac-2-(5-bromobenzo[d]thiazol-2-yl)pyrrolidine-1 -carboxylate (280 mg, 33.1% yield, 95% purity) as a light brown solid. LCMS (ES, m / z): 505.2 [M+H]+.
[0151] Step 4: A solution of (9H-fluoren-9-yl)methyl rac-2-(5-bromobenzo[d]thiazol-2-yl)pyrrolidine-1 -carboxylate (260 mg, 0.514 mmol, 1.00 equiv) and piperidine (1.0 mL, 3.4 mmol, 2.0 equiv) in DMF (3 mL) was stirred at room temperature for 1 hour. The resulting solution was directly purified directly by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 50% to 70% gradient in 20 min; detector,UV 254 nm. This resulted in (R)-5-bromo-2-(pyrrolidin-2-yl)benzo[d]thiazole (120 mg, 82.4% yield, 97% purity) as an off-white solid. LCMS (ES, m / z): 283.1 [M+H]+.
[0152] Step 5: To a stirred solution of rac-5-bromo-2-(pyrrolidin-2-yl)benzo[d]thiazole (110 mg, 0.388 mmol, 1.00 equiv) and 1-cyclopropyl-4-isocyanato-2-(trifluoromethyl)benzene (150 mg, 0.660 mmol, 1.70 equiv) in THF (2 mL) was added NMM (80 mg, 0.79 mmol, 2.0 equiv) at room temperature. The resulting mixture was stirred at room temperature for 1 hour. The resulting mixture was diluted with water (50 mL). The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (1 x 40 mL), dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE I EA (1:1) to afford rac-2-(5-bromobenzo[d]thiazol-2-yl)-N-(4-cyclopropyl-3-(trifluoromethyl)phenyl)pyrrolidine-1-carboxamide (30 mg, 15.1% yield, 97% purity) as an off-white solid. LCMS (ES, m / z): 510.1 [M+H]+.
[0153] Step 6: To a stirred solution of rac-2-(5-bromobenzo[d]thiazol-2-yl)-N-(4-cyclopropyl-3-(trifluoromethyl)phenyl)pyrrolidine-1 -carboxamide (25 mg, 0.049 mmol, 1.0 equiv) and 4-(4, 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (18 mg, 0.073 mmol, 1.5 equiv) in dioxane (0.50 mL) and H2O (0.10 mL) were added Pd(dppf)Ch (7 mg, 0.010 mmol, 0.20 equiv) and K2CO3 (17 mg, 0.123 mmol, 2.5 equiv) at room temperature. The resulting mixture was stirred at 80°C for 1 h under nitrogen atmosphere. The resulting solution was concentrated under vacuum, and then the residue was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 20% to 40% gradient in 20 min; detector, UV 254 nm to afford amount of racemic product. The racemic product was separated by Pre-Chiral-HPLC with the following conditions (Column: CHIRALPAK IF, 2*25 cm, 5 pm; Mobile Phase A: Hex(0.2% FA)-HPLC, Mobile Phase B: MeOH: DCM=1: 1-HPLC; Flow rate: 20 mL / min; Gradient (B%): 30% B to 30% B in 20 min% B; Wave Length: 220 / 254 nm; RT1(min): 10.88; RT2(min): 16.23; Sample Solvent: MeOH: DCM=1: 1-HPLC; Injection Volume: 3.3 mL; Number Of Runs: 1) to afford, in order of elution, Compound 8(lsomer 1) (5.1 mg, 18.88% yield, 99.6% purity) as an off-white solid and Compound 8(lsomer 2)(4.8 mg, 17.8% yield, 99.6% purity) as a light brown solid.
[0154] Compound 8(lsomer 1): The absolute stereochemistry of Isomer 1 was not assigned but corresponds to one of Compounds 8(a) and 8(b). Chiral separation: RT1(min): 10.88. LCMS (ES, m / z): 552.2 [M+H]+;1HNMR (300 MHz, DMSO-cfe) 6 12.99 (s, 1H), 8.77 (s, 1H), 8.30 (d, J = 1.5 Hz, 1H), 8.16 (d, J= 8.4 Hz, 1H), 8.05 (d, J= 8.4 Hz, 2H), 7.95-7.90 (m, 3H), 7.81-7.77 (m, 1H), 7.71-7.68 (m, 1H), 7.06 (d, J = 9.0 Hz, 1H), 5.48-5.46 (m, 1H), 3.81-3.78 (m, 1H), 3.60-3.57 (m,1 H), 2.42-2.39 (m, 1H), 2.22-2.10 (m, 1 H), 2.12-2.01 (m, 3H), 0.97 - 0.92 (m, 2H), 0.74-0.69 (m, 2H).
[0155] Compound 8(lsomer 2): The absolute stereochemistry of Isomer 2 was not assigned but corresponds to the other of Compounds 8(a) and 8(b). Chiral separation: RT2(min): 16.23. LCMS (ES, m / z): 552.2 [M+H]+;1H NMR (300 MHz, DMSO-cfe) 6 12.99 (s, 1H), 8.77 (s, 1H), 8.30 (d, J = 1.5 Hz, 1H), 8.16 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 8.4 Hz, 2H), 7.95 - 7.90 (m, 3H), 7.81-7.77 (m, 1H), 7.71-7.68 (m, 1H), 7.06 (d, J= 9.0 Hz, 1H), 5.48-5.46 (m, 1H), 3.81-3.78 (m, 1H), 3.60-3.57 (m, 1H), 2.42-2.39 (m, 1H), 2.22-2.10 (m, 1H), 2.12-2.01 (m, 3H), 0.97 - 0.92 (m, 2H), 0.74-0.69 (m, 2H).(ix) (R)-3-(2-(1-((4-cyclopropyl-3-(trifluoromethyl)phenyl)carbamoyl)pyrrolidin-2-yl)- 1 H-benzo[d]imidazol-5-yl)benzoic acid (Compound 9(a))
[0156] Compound 9(a) is prepared according to the General Procedures shown in Scheme 1 using 1-cyclopropyl-4-isocyanato-2-(trifluoromethyl)benzene as lnt-1 and (tert-butoxycarbonyl)-D-proline as lnt-2, 4-bromobenzene-1,2-diamine as the 1 ,2-dianiline and 3-boronobenzoic acid as the coupling partner.
[0157] LCMS (ES, m / z):535.1 [M+H]+;1H NMR (400 MHz, DMSO-cfe) 59.43 (s, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.87-7.85 (m, 1H), 7.73-7.66 (m, 2H), 7.57-7.54 (m, 2H), 7.42-7.34 (m, 2H), 6.99 (d, J = 8.4 Hz, 1H), 5.42-5.36 (m, 1H), 3.88-3.82 (m, 1H), 3.58-3.53 (m, 1H), 2.37 - 2.30 (m, 1H), 2.21-2.08 (m, 2H), 2.00-1.93 (m, 2H), 0.92-0.89 (m, 2H), 0.68-0.65 (m, 2H).(x) (R)-4-(2-(1-((4-isopropylphenyl)carbamoyl)pyrrolidin-2-yl)benzo[d]thiazol-5-yl)benzoic acid (Compound 50(a)) and (S)-4-(2-(1-((4-isopropylphenyl)carbamoyl)pyrrolidin-2-yl)benzo[d]thiazol-5-yl)benzoic acid (Compound 50(b))
[0158] Compounds 50(a) and 50(b) are prepared according to Scheme 4 with the following modification: 1-cyclopropyl-4-isocyanato-2-(trifluoromethyl)benzene is replaced with 1-isocyanato-4-isopropylbenzene.
[0159] The mixture of enantiomers obtained after the final step was separated by chiral prep-HPLC [column: Lux Cellulose-4 2.12*25 cm, 5 pm; mobile phase A: hexane (0.2% FA); mobile phase B: MeOH:EtOH = 1 :1 ; flow rate: 20 mL / min; gradient: isocratic 40% B in 18 min; RT1 (min): 7.3; RT2 (min): 14.8] to afford, in order of elution, Compound 50(lsomer 1) and Compound 50(lsomer 2).
[0160] Compound 50(lsomer 1): The absolute stereochemistry of Compound 50(lsomer 1) was not assigned but corresponds to one of Compounds 50(a) and 50(b). Chiral separation: RT1 (min): 7.3. LCMS (ES, m / z): 485.6 [M+H]+.1H NMR (400 MHz, DMSO-cfe) 6 12.99 (s, 1 H), 8.44 (s, 1 H), 8.30 - 8.19 (m, 1 H), 8.16 - 8.09 (m, 1 H), 8.08 - 8.01 (m, 2H), 7.95 - 7.89 (m, 2H), 7.79-7.62 (m, 1 H), 7.44 - 7.36 (m, 2H), 7.14 - 7.06 (m, 2H), 5.46 - 5.37 (m, 1 H), 3.81 - 3.73 (m, 1 H), 3.62 - 3.52 (m, 1 H), 2.81 - 2.67 (m, 1 H), 2.47 - 2.36 (m, 1 H), 2.25 - 2.15 (m, 1 H), 2.13 - 1.95 (m, 2H), 1.22 - 1.12 (m, 6H).
[0161] Compound 50(lsomer 2): The absolute stereochemistry of Compound 50(lsomer 2) was not assigned but corresponds to the other of Compounds 50(a) and 50(b). Chiral separation: RT2 (min): 14.8. LCMS (ES, m / z): 485.6 [M+H]+.1H NMR (400 MHz, DMSO-cfe) 6 12.99 (s, 1 H), 8.44 (s, 1 H), 8.30 - 8.19 (m, 1 H), 8.16 - 8.09 (m, 1 H), 8.08 - 8.01 (m, 2H), 7.95 - 7.89 (m, 2H), 7.79-7.62 (m, 1 H), 7.44 - 7.36 (m, 2H), 7.14 - 7.06 (m, 2H), 5.46 - 5.37 (m, 1 H), 3.81 - 3.73 (m, 1 H), 3.62 - 3.52 (m, 1 H), 2.81 - 2.67 (m, 1 H), 2.47 - 2.36 (m, 1 H), 2.25 - 2.15 (m, 1 H), 2.13 - 1.95 (m, 2H), 1.22 - 1.12 (m, 6H).Example 3: In vitro biological activity
[0162] Compounds were tested for GIPR antagonism by a cAMP assay by the following manner:1) Prepare the cAMP assay buffer following the table below:Reagent Vol.1x HBSS with Ca2+and Mg2+14 mL1 M HEPES 75 pL7.5% (w / v) BSA stabilizer (pH 7.4) 100 pL500 mM IBMX 14 L2) Prepare the Eu-cAMP tracer working solution and Ulight-anti-cAMP working solution following the table below:Eu-cAMP tracer working solution Ulight-anti-cAMP working solution Reagent Vol. Reagent Vol.Eu-cAMP tracer Stock 20 pl Ulight-anti-cAMP Stock 10 pl cAMP detection Buffer 2 ml cAMP detection Buffer 2 ml3) Preparation of the compound source plate:a. Preparation of 10 doses of GIP starting from 10uM stock solution by 4-fold serial dilutions with water.b. Preparation of 10 doses of reference compound GIP3-30 starting from 2 mM stock solution by 4-fold serial dilutions with water.c. Preparation of 10 doses of reference compound and test compounds starting from 10 mM stock solution by 3-fold serial dilutions with 100% (v / v) DMSO.4) Preparation of assay plate:a. Before the assay, harvest cells stably expressing GIP receptors and count the cells using a Countess cell counter. Only cells with viability >85% are used for the following assay.b. Dilute cells to 1x105 cells / mL with the cAMP assay buffer.c. Seed cells at a density of 1000 cells / well in 384-well plate.5) Transfer 10 nL / well of GIP to each well of the assay plate with GIP receptor-expressing cells by an Echo.6) Centrifuge the cell plate at 1000 rpm for 1 min and then agitate at 600 rpm for 2 min. Incubate the plate at 37°C for 30 min.7) Add 5 pL / well of Eu-cAMP tracer working solution and 5 pL / well of Ulight-anti-cAMP working solution to each well of the plate. Centrifuge the plate at 1000 rpm for 1 min and then agitate at 600 rpm for 2 min. Incubate the plate at RT for 60 min.8) Read the plate by using an EnVison microplate reader (Aex=337 nm, Aem=615 nm and 665 nm), and plot the ratio of Emission665 nm to Emission615 nm against the concentrations of compounds to build the curve and calculate the EC50 and EC80 of GIP.9) Dilute cells to 1xio5cells / mL with the cAMP assay buffer. Seed cells at a density of 1000 cells / well in 384-well plate.10) Transfer 50 nL / well of reference compound and 10 nL / well of test compounds to each well of the assay plate with GIP receptor-expressing cells by an Echo.11) Centrifuge the cell plate at 1000 rpm for 1 min and then agitate at 600 rpm for 2 min. Incubate the plate at 37 °C for 10 min.12) Transfer appropriate amount of GIP to reach its EC80 value to each well of the assay plate with GIP receptor-expressing cells by an Echo.13) Centrifuge the cell plate at 1000 rpm for 1 min and then agitate at 600 rpm for 2 min. Incubate the plate at 37°C for 30 min.14) Add 5 pL / well of Eu-cAMP tracer working solution and 5 pL / well of Ulight-anti-cAMP working solution to each well of the plate. Centrifuge the plate at 1000 rpm for 1 min and then agitate at 600 rpm for 2 min. Incubate the plate at RT for 60 min.15) Read the plate by using an EnVison microplate reader (Aex=337 nm, Aem=615 nm and 665 nm), and plot the ratio of Emission665 nm to Emission615 nm against the concentrations of compounds to build the curve and calculate the IC50.
[0163] Percent inhibition was then calculated in the following manner:1) Calculate the ratio of TR-FRET signal using following equation:Ratio = Aem (665 nm) / Aem (620 nm)2) Calculate the % Inhibition (for antagonist) using following equation:Ratiocpd— RatioHCInhibition (%) = 100 — 100 xRatioLC— RatioHCRationc: The ratio of TR-FRET signal of high control (HC stands for high control).Ratiotc: The ratio of TR-FRET signal of low control (LC stands for low control).RatiOcpd: The ratio of TR-FRET signal of test compound-treated group (cpd stands for compound).3) The IC50 is determined by fitting the dose response curve with Hill equation using XLfit.Table 2. Biological activity of selected Compounds GIPRcAMP IC50 (pM) GIPRcAMP IC50 (pM) Compound(10 min. incubation) (2 h incubation)1(a) 0.75 - 2(a) 4.5 - 3(a) 1.6 - 4(a) >10 - 5(a) >10 - 6(a) 2.6 - 7(a) 7.4 - 8(lsomer 1) >10 - 8(lsomer 2) 0.67 - 9(a) 7.2 - 50(lsomer 1) - >1050(lsomer 2) - 0.11
[0164] Numerous modifications could be made to any of the embodiments described above without departing from the scope of the present invention. Any references, patents or scientific literature documents referred to in the present document are incorporated herein by reference in their entirety for all purposes.
Claims
Claims1. A compound of Formula (I):NHor a pharmaceutical acceptable salt, solvate, or prodrug thereof,wherein:X is selected from -CR2R2’-, -O- and -NR2-;XIis selected from -CR1R1’-, -O- and -NR1-;X3is selected from -O-, -NH- and -S-;X4is selected from -N=, -CH= and -CR7=;provided that when one of X and X1is -CR2R2’- or -CR1R1’-, then the other of X and X1is other than -CR2R2’- or -CR1R1’-, and provided that when one of X and X1is -O-, -NR1- or - NR2-, then the other of X and X1is other than -O-, -NR1- or -NR2-;Y1, Y2, Y3and Y4are independently selected from -N=, -CH= and -CR8=, and one of Y1,_ OY2, Y3and Y4is -C= to allow the connection with OH ;R1, R1’, R2and R2’ are independently selected from -H, linear or branched Ci-Cealkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, - SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally furthersubstituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’; or R1and R2are taken together with their adjacent atoms to form a ring, the ring being optionally substituted with one or more substituents; or R1and R1’ are taken together with their adjacent carbon atom to form a ring, the ring being optionally substituted with one or more substituents; or R2and R2’ are taken together with their adjacent carbon atom to form a ring, the ring being optionally substituted with one or more substituents;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;R7is a linear or branched Ci-Cealkyl;R8is selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, -NR4S(=O)2-R5and -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;is selected from the group consisting of 4- to 14-membered heterocycloalkyl, Ce- Cwaryl and 5- to 10-membered heteroaryl each optionally linked to NH through a Ci- Csalkyl group, the 4- to 14-membered heterocycloalkyl, Ce-Cwaryl or 5- to 10-membered heteroaryl being optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -OR3, SFs, or -SR3, wherein the linear or branched Ci-Cealkyl and Cs-Cscycloalkyl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3; and( B )- is selected from the group consisting of linear or branched Ci-Cealkyl, C2- Csalkyne, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10- membered heteroaryl, the linear or branched Ci-Cealkyl, C2-Csalkyne, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl or 5- to 10-membered heteroaryl being optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -C(=O)OH, -OR3, -SFs, or - SR3, wherein the linear or branched Ci-Cealkyl and Cs-Cscycloalkyl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3.
2. The compound of claim 1 , wherein the compound is of formula (I’) is:X is selected from -CR2R2’-, -O- and -NR2-;XIis selected from -CR1R1’-, -O- and -NR1-;X3is selected from -O-, -NH- and -S-;X4is selected from -N=, -CH= and -CR7=;provided that when one of X and X1is -CR2R2’- or -CR1R1’-, then the other of X and X1is other than -CR2R2’- or -CR1R1’-, and provided that when one of X and X1is -O-, -NR1- or -NR2-, then the other of X and X1is other than -O-, -NR1- or -NR2-;Y1, Y2and Y4are independently selected from -N=, -CH= and -CR8=;R1, R1’, R2and R2’ are independently selected from -H, linear or branched Ci-Cealkyl, C3-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’; or R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, the 4- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents; or R1and R1’ are taken together with their adjacent carbon atom to form a Cs-Cscycloalkyl, the C3-Cscycloalkyl being optionally substituted with one or more substituents; or R2and R2’ are taken together with their adjacent carbon atom to form a Cs-Cscycloalkyl, the C3-Cscycloalkyl being optionally substituted with one or more substituents;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, whereinthe Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;R7is a linear or branched Ci-Cealkyl;R8is selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, -NR4S(=O)2-R5and -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;(A)' is selected from the group consisting of 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl each optionally linked to NH through a Ci-Cealkyl group, the 4- to 14-membered heterocycloalkyl, Ce-Cwaryl or 5- to 10-membered heteroaryl being optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, Cs-Cscycloalkyl, 4-to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -OR3, SFs, or -SR3, wherein the linear or branched Ci-Cealkyl and Cs-Cscycloalkyl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3; andis selected from the group consisting of 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, the 4- to 14-membered heterocycloalkyl, Ce-Cwaryl or 5- to 10-membered heteroaryl being optionally substitutedwith one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce- Cwaryl, 5- to 10-membered heteroaryl, -OR3, SF5, or -SR3, wherein the linear or branched Ci-Cealkyl and Cs-Cscycloalkyl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3.(A)3. The compound of claim 1 or 2, wherein ' is a 4- to 14-membered heterocycloalkyl or Ce-Cwaryl optionally substituted with one or more substituents, the substituents being preferably selected from halogen, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14- membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -OR3or -SR3, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, the substituents being preferably selected from(A)halogens or -CF3; and wherein is optionally linked to NH through a Ci-Csalkyl group.
4. The compound of any one of claims 1 to 3, whereinis a 5-membered heteroaryl optionally substituted with one or more substituents, the substituents being preferably selected from halogen, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -OR3or -SR3, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce- C aryl, 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3; and(A)wherein ' is optionally linked to NH through a Ci-Csalkyl group.The compound of claim 4, whereinR9whereinis optionally linked to NH through a Ci-Csalkyl group;wherein R9is independently in each occurrence selected from the group consisting of halogen, -OR3, SR3, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, preferably selected from halogens, -CF3, linear or branched C1- Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, and 5- to 10- membered heteroaryl, andwherein R3is selected from the group consisting of -H, -CF3 and linear or branched C1- Cealkyl optionally substituted with one or more substituents.
6. The compound of claim 4, whereinN'NS, and whereinis optionally linked to NH through a Ci-Csalkyl group.
7. The compound of any one of claims 1 to 3, whereinisR9is independently in each occurrence selected from the group consisting of halogen, - OR3, -SR3, -SF5, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, or two R9on adjacent atoms are taken together to form a Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl or 5- to 10-membered heteroaryl, wherein the Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents preferably selected from halogens, - CF3, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl; andwherein R3is selected from the group consisting of -H and linear or branched Ci-Cealkyl optionally substituted with one or more substituents preferably selected from halogens.
8. The compound of claim 7, wherein R9is independently selected from the group consisting of -Cl, -F, -CF3, -OCF3, -SCF3, -SF5, -OCH3, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl,4- to 14-membered heterocycloalkyl, each optionally further substituted, preferably with one or more -CF3.group.10.C B )11. The compound of any one of claims 1 to 10, wherein- is selected from linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, Ce-C aryl or 5- to 10-membered heteroaryl being optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, and -OR3.12.,O13. The compound of claim 12, whereinOH is15. The compound of any one of claims 1 to 14, wherein the compound is of Formula I’a:or a pharmaceutical acceptable salt, solvate, or prodrug thereof,wherein R1, R1’, X,X3, X4, Y1, Y2, Y4and are as defined in any one of claims 1 to 14.
16. The compound of claim 15, wherein R1and R1’ are independently selected from -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci- Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci- Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of - H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of - H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;or R1and R1’ are taken together with their adjacent carbon atom to form a Cs-Cscycloalkyl, the Cs-Cscycloalkyl being optionally substituted with one or more substituents.
17. The compound of claim 15 or 16, wherein X is -O-.
18. The compound of claim 15 or 16, wherein X is -NR2-.
19. The compound of claim 18, wherein R2is selected from -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -CN, -OR3, - SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-memberedheterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents preferably selected from halogens, -OR3, - NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci- Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci- Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of - H, linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of - H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;or R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, the 4- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents.
20. The compound of any one of claims 1 to 14, wherein the compound is of Formula I’b:or a pharmaceutical acceptable salt, solvate, or prodrug thereof,wherein R2, R2’, X1, X3, X4,and are as defined in any one of claims 1 to 14.
21. The compound of claim 20, wherein R2and R2’are independently selected from -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, - NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci- Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci- Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of - H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, whereinthe Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of - H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;or R2and R2’ are taken together with their adjacent carbon atom to form a Cs-Cscycloalkyl, the Cs-Cscycloalkyl being optionally substituted with one or more substituents.
22. The compound of claim 20 or 21 , wherein X1is -O-.
23. The compound of claim 20 or 21 , wherein X1is -NR1-.
24. The compound of claim 23, wherein R1is selected from -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -CN, -OR3, - SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents preferably selected from halogens, -OR3, - NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci- Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci- Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of - H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, whereinthe Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of - H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;or R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, the 4- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents.
25. The compound of any one of claims 1 to 24, wherein R1, R1’, R2and R2’ are independently selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl and Ce-Cwaryl, optionally substituted with one or more substituents, the substituents being preferably selected from -Cl, -F, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl and Ce-Cwaryl.
26. The compound of claim 25, wherein R1, R1’, R2and R2’ are independently selected from the group consisting of -H, -CH3, -CH2CH3, -CH(CH3)2, -CH2CF2CH3, cyclopropyl,cyclopentyl, cyclohexyl, phenyl,27. The compound of claim 26, wherein R1is -CH3 and R1’ is -H or -CH3.
28. The compound of claim 26 or 27, wherein R2is -CH3 and R2’ is -H or -CH3.
29. The compound of any one of claims 1 to 19, wherein R1and R1’ are taken together with their adjacent carbon to form a cyclopropyl.
30. The compound of any one of claims 1 to 14 and 20 to 24, wherein R2and R2’ are taken together with their adjacent carbon to form a cyclopropyl.
31. The compound of any one of claims 1 to 24, wherein R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, the 4- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents.
32. The compound of claim 31 , wherein R1and R2are taken together with their adjacent atoms to form a 6- to 14-membered heterocycloalkyl, the 6- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents.
33. The compound of claim 32, wherein the 6- to 14-membered heterocycloalkyl iswhereinq is between 1 and 2; andX5is -CH2-, -NR11-, -S- or-O-;R11is selected from the group consisting of -H, linear or branched Ci-Cealkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl and Ce-C aryl, optionally substituted with one or more substituents; andwherein the 6- to 14-membered heterocycloalkyl is optionally further substituted with one or more substituents.
34. The compound of claim 33, wherein the 6- to 14-membered heterocycloalkyl is of formulaNor , wherein q and X5are as previously defined, and is optionally further substituted with one or more substituents.
35. The compound of claim 34, wherein q is 1.
36. The compound of claim 34, wherein q is 2.
37. The compound of any one of claims 33 to 36, wherein X5is -CH2-.
38. The compound of any one of claims 33 to 36, wherein X5is -O-.
39. The compound of claim 31 , wherein R1and R2are taken together with their adjacent atoms to form a 4- or 5-membered heterocycloalkyl, the 4- or 5-membered heterocycloalkyl being optionally substituted with one or more substituents.
40. The compound of claim 39, wherein the 4- or 5-membered heterocycloalkyl is a 5- membered heterocycloalkyl, optionally substituted with one or more substituents.
41. The compound of claim 40, wherein the 5-membered heterocycloalkyl is of formula:
42. The compound of any one of claims 31 to 41, wherein the heterocycloalkyl is substituted with one or more R10substituents independently in each occurrence selected from the group consisting of halogen, -CN, OR3, SR3, -NR4R4’, -NR4C(=O)R5, -C(=O)-NR6R6’, =0 (oxo), -S(=O)2-R5, -NR4S(=O)2R5, -S(=O)2-NR6R6’, linear or branched Ci-C6alkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, or two R10are taken together with their adjacent carbon atom(s) to form a fused, spiro or bridged Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl or5- to 10-membered heteroaryl, wherein the Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14- membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents preferably selected from halogens, -CN, OR3, - NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -CF3, linear or branched Ci-C6alkyl, C3-C8cycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, wherein R3, R4, R4’, R5, R6and R6’ are previously defined.
43. The compound of any one of claims 31 to 41, wherein the heterocycloalkyl is unsubstituted.
44. The compound of any one of claims 1 to 43, wherein X3is -S-.
45. The compound of any one of claims 1 to 43, wherein X3is -NH-.
46. The compound of any one of claims 1 to 43, wherein X3is -O-.
47. The compound of any one of claims 1 to 46, wherein X4is -N=.
48. The compound of any one of claims 1 to 46, wherein X4is -CH=.
49. The compound of any one of claims 1 to 48, wherein Y1is -N=, Y2is -CH= and Y3is -CH=.
50. The compound of any one of claims 1 to 48, wherein Y1is -CH=, Y2is -N= and Y3is -CH=.
51. The compound of any one of claims 1 to 48, wherein Y1is -CH=, Y2is -CH= and Y3is -N=.
52. The compound of claim 1, which is one of Compounds 1 to 50 of Table 1 of the description, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
53. The compound of claim 1, which is one of Compounds 1(a), 8(lsomer 2), and 50(lsomer 2) as defined herein, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
54. The compound of any one of claims 1 to 53, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the compound is in the form of a racemate or any enantiomer thereof.
55. A pharmaceutical composition comprising: a compound according to any one of claims 1 to 53, or a pharmaceutically acceptable salt, solvate, or prodrug thereof; and a pharmaceutically acceptable carrier, diluent or excipient.
56. Use of a compound as defined in any one of claims 1 to 53, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for the preparation of a pharmaceutical composition for the treatment or prevention of a condition, a disease or a disorder for which modulating the glucose-dependent insulinotropic polypeptide receptor (GIPR) is indicated.
57. Use of a compound as defined in any one of claims 1 to 53, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for the preparation of a pharmaceutical composition for the treatment or prevention of a condition, a disease or a disorder selected from metabolic diseases and obesity.
58. Use of a compound as defined in any one of claims 1 to 53, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for the preparation of a pharmaceutical composition for the treatment or prevention of a condition, a disease or a disorder selected from diabetes (e.g. Type 1 diabetes mellitus (T1D), Type 2 diabetes mellitus (T2DM), including pre-diabetes), idiopathic T1D (Type 1b), latent autoimmune diabetes in adults (LADA), early-onset T2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflam matory changes to the proximal tubules, or chronic kidney disease (CKD)), diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea (e.g. obstructive sleep apnea (OSA)), obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urine incontinence), eating disorders (including binge eating syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndromes), weight gain such as weight gain caused by use of other agents (e.g., caused by use of steroids and / or antipsychotics, or caused by treatment of depression, or caused by use of agents on cognitive function), excessive sugar craving, dyslipidemia [including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high LDL (low-density lipoprotein) cholesterol, and low HDL (high-density lipoprotein) cholesterol], hyperinsulinemia, nonalcoholic fatty liver disease [NAFLD, including related diseases such as steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma], cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, heart failure (e.g. congestive heart failure, heart failure with preserved ejection fraction(HFpEF), heart failure with reduced ejection fraction (HFrEF)), myocardial infarction (e.g. necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, osteoarthritis, Parkinson’s disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, polycystic ovary syndrome (PCOS), and addiction (e.g., addiction to alcohol, nicotine, and / or drug).
59. Use of a compound as defined in any one of claims 1 to 53, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for the manufacture of a medicament for the treatment or prevention of a condition, a disease or a disorder for which modulating the glucose-dependent insulinotropic polypeptide receptor (GIPR) is indicated.
60. Use of a compound as defined in any one of claims 1 to 53, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for the manufacture of a medicament for the treatment or prevention of a condition, a disease or a disorder selected from metabolic diseases and obesity.
61. Use of a compound as defined in any one of claims 1 to 53, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for the manufacture of a medicament for the treatment or prevention of a condition, a disease or a disorder selected from diabetes (e.g. Type 1 diabetes mellitus (T1D), Type 2 diabetes mellitus (T2DM), including pre-diabetes), idiopathic T1D (Type 1b), latent autoimmune diabetes in adults (L DA), early-onsetT2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, or chronic kidney disease (CKD)),diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea (e.g. obstructive sleep apnea (OSA)), obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urine incontinence), eating disorders (including binge eating syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndromes), weight gain such as weight gain caused by use of other agents (e.g., caused by use of steroids and / or antipsychotics, or caused by treatment of depression, or caused by use of agents on cognitive function), excessive sugar craving, dyslipidemia [including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high LDL (low-density lipoprotein) cholesterol, and low HDL (high-density lipoprotein) cholesterol], hyperinsulinemia, nonalcoholic fatty liver disease [NAFLD, including related diseases such as steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma], cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, heart failure (e.g. congestive heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF)), myocardial infarction (e.g. necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, osteoarthritis, Parkinson’s disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, polycystic ovary syndrome (PCOS), and addiction (e.g., addiction to alcohol, nicotine, and / or drug).
62. A method for treating or preventing a disorder for which modulation of the glucosedependent insulinotropic polypeptide receptor (GIPR) is indicated comprising administering to a patient in need thereof a compound as defined in any one of claims 1 to 53, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
63. A method for treating or preventing a condition, a disease or a disorder selected from metabolic diseases and obesity comprising administering to a patient in need thereof a compound as defined in any one of claims 1 to 53, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
64. A method for treating or preventing a condition, a disease or a disorder comprising administering to a patient in need thereof a compound as defined in any one of claims 1 to 53, or a pharmaceutical acceptable salt, solvate, or prodrug thereof, wherein the condition, disease or disorder is selected from diabetes (e.g. Type 1 diabetes mellitus (T1D), Type 2 diabetes mellitus (T2DM), including pre-diabetes), idiopathic T1D (Type 1b), latent autoimmune diabetes in adults (LADA), early-onset T2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition- related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinfl am matory changes to the proximal tubules, or chronic kidney disease (CKD)), diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea (e.g. obstructive sleep apnea (OSA)), obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urine incontinence), eating disorders (including binge eating syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndromes), weight gain such as weight gain caused by use of other agents (e.g., caused by use of steroids and / or antipsychotics, or caused by treatment of depression, or caused by use of agents on cognitive function), excessive sugar craving, dyslipidemia [including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high LDL (low-density lipoprotein) cholesterol, and low HDL (high-density lipoprotein) cholesterol], hyperinsulinemia, nonalcoholic fatty liver disease [NAFLD, including related diseases such as steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma], cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, heart failure (e.g. congestive heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF)), myocardial infarction (e.g. necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis,osteoporosis, osteoarthritis, Parkinson’s disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, polycystic ovary syndrome (PCOS), and addiction (e.g., addiction to alcohol, nicotine, and / or drug).
65. A compound according to any one of claims 1 to 53, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for use in the treatment or prevention of a condition, a disease, or a disorder for which modulation of the glucose-dependent insulinotropic polypeptide receptor (GIPR) is indicated.
66. A compound according to any one of claims 1 to 53, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for use in the treatment or prevention of a condition, a disease or a disorder selected from metabolic diseases and obesity.
67. A compound according to any one of claims 1 to 53, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for use in the treatment or prevention of a condition, a disease or a disorder selected from diabetes (e.g. Type 1 diabetes mellitus (T 1 D), Type 2 diabetes mellitus (T2DM), including pre-diabetes), idiopathic T1D (Type 1b), latent autoimmune diabetes in adults (LADA), early-onset T2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, or chronic kidney disease (CKD)), diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea (e.g. obstructive sleep apnea (OSA)), obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urine incontinence), eating disorders (including binge eating syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndromes), weight gain such as weight gain caused by use of other agents (e.g., causedby use of steroids and / or antipsychotics, or caused by treatment of depression, or caused by use of agents on cognitive function), excessive sugar craving, dyslipidemia [including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high LDL (low-density lipoprotein) cholesterol, and low HDL (high-density lipoprotein) cholesterol], hyperinsulinemia, nonalcoholic fatty liver disease [NAFLD, including related diseases such as steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma], cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, heart failure (e.g. congestive heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF)), myocardial infarction (e.g. necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, osteoarthritis, Parkinson’s disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, polycystic ovary syndrome (PCOS), and addiction (e.g., addiction to alcohol, nicotine, and / or drug).
